Bladder cancer is a type of cancer that starts in the cells of the bladder, the organ responsible for storing urine.
It can cause symptoms like blood in urine, frequent urination, and requires various treatments depending on its stage and severity.
In Singapore, there are various treatment options available for bladder cancer. The specific treatment plan will depend on various factors such as the stage of the cancer, the grade of the tumour, the patient’s overall health, and other individual factors.
Surgery is a common treatment for bladder cancer and can involve procedures such as transurethral resection of bladder tumour (TURBT) to remove small tumours, partial or radical cystectomy to remove part or all of the bladder, and urinary diversion techniques for redirecting urine flow after bladder removal.
Transurethral resection of bladder tumour (TURBT):
Partial or radical cystectomy:
Lymphadenectomy:
Radiation therapy is a common treatment option for bladder cancer.
(A) External Beam Radiation Therapy: This involves using a machine called a linear accelerator to deliver high-energy X-rays to the tumour from outside the body. The radiation beams are carefully targeted to the bladder, aiming to kill cancer cells while minimising damage to surrounding healthy tissues.
(B) Internal Radiation Therapy (Brachytherapy): Radioactive material, such as seeds or wires, is temporarily placed inside the bladder. These radioactive sources emit radiation directly to the tumour, delivering a concentrated dose of radiation while sparing healthy tissues.
(C) Combination Therapy: Radiation therapy can be combined with other treatments, such as surgery or chemotherapy, to increase effectiveness. It may be used before surgery (neoadjuvant therapy) to shrink tumours or after surgery (adjuvant therapy) to target any remaining cancer cells.
(D) Palliative Radiation Therapy: In advanced cases or when bladder cancer has spread, radiation therapy can be used to alleviate symptoms, such as pain, bleeding, or urinary obstruction, and improve quality of life.
Chemotherapy is a treatment option for bladder cancer that uses drugs to kill cancer cells or slow down their growth.
(A) Intravesical Chemotherapy: Chemotherapy drugs are directly instilled into the bladder through a catheter. This method is often used for early-stage bladder cancer or to prevent recurrence after tumour removal. Common drugs used include mitomycin C or bacillus Calmette-Guérin (BCG).
(B) Systemic Chemotherapy: Drugs are given intravenously or orally to target cancer cells throughout the body. Systemic chemotherapy may be used before or after surgery, or in advanced cases where cancer has spread beyond the bladder. The choice of drugs and regimen depends on the specific characteristics of the cancer and the patient’s overall health.
(C) Combination Therapy: Different chemotherapy drugs can be combined to enhance their effectiveness. Combination chemotherapy is commonly used in advanced bladder cancer to improve treatment outcomes. Platinum-based drugs, such as cisplatin or carboplatin, are often used in combination with other drugs like gemcitabine or paclitaxel.
(D) Neoadjuvant and Adjuvant Chemotherapy: Neoadjuvant chemotherapy is given before surgery to shrink tumours and increase the likelihood of successful surgery. Adjuvant chemotherapy is administered after surgery to target any remaining cancer cells and reduce the risk of recurrence.
Targeted therapy is an emerging treatment approach for bladder cancer that aims to specifically target certain genetic mutations or pathways in cancer cells.
(A) Molecular Targeted Therapy: Targeted therapy drugs are designed to block specific molecules or pathways involved in the growth and spread of cancer cells. These drugs work differently than traditional chemotherapy by specifically targeting cancer cells while sparing normal cells.
(B) FGFR Inhibitors: Fibroblast growth factor receptor (FGFR) inhibitors are a type of targeted therapy used for bladder cancer with specific genetic alterations in FGFR genes. Drugs like erdafitinib or pemigatinib are used to inhibit abnormal FGFR signaling and slow down cancer growth.
(C) PD-1/PD-L1 Inhibitors: Immune checkpoint inhibitors, such as pembrolizumab or atezolizumab, are targeted therapy drugs that enhance the immune system’s ability to recognise and attack cancer cells.
(D) HER2 Inhibitors: Bladder cancers that overexpress human epidermal growth factor receptor 2 (HER2) may benefit from targeted therapy drugs like trastuzumab or pertuzumab. These drugs specifically target HER2-positive cancer cells and interfere with their growth signals.
Targeted therapy drugs can be used in combination with other treatment modalities like chemotherapy or immunotherapy to maximise treatment effectiveness.
Immunotherapy is a type of bladder cancer treatment that works by boosting the body’s immune system to recognize and attack cancer cells.
Immune Checkpoint Inhibitors: Immunotherapy drugs called immune checkpoint inhibitors, such as pembrolizumab or atezolizumab, are used in bladder cancer treatment.
Immunotherapy can lead to durable responses and long-term control of bladder cancer. It is used in advanced cases when cancer has spread or as an option when other treatments have not been effective. However, not all patients respond to immunotherapy, and the effectiveness may vary from person to person.
Surgery is a common treatment for bladder cancer and, like any medical procedure, it can have potential side effects. Here are some common side effects associated with bladder cancer surgery:
Radiation therapy is a common treatment for bladder cancer, and it can have certain side effects. Here are some common side effects associated with bladder cancer treatment using radiation therapy:
Chemotherapy, a common treatment for bladder cancer, can have certain side effects. Here are some common side effects associated with bladder cancer treatment using chemotherapy:
Targeted therapy is a newer treatment approach for bladder cancer, and it can have certain side effects. Here are some common side effects associated with bladder cancer treatment using targeted therapy:
Immunotherapy, a treatment option for bladder cancer, can have certain side effects. Here are some common side effects associated with bladder cancer treatment using immunotherapy:
It is important to remember that bladder cancer can be treated successfully if caught early. If you have any concerns about your bladder health or notice any changes, do not hesitate to see a healthcare professional for evaluation.
If you suspect that you or your loved one have bladder cancer, it is advisable to get the support you need. Early detection and diagnosis of bladder cancer is key to treating the disease.
Regardless of what stage your bladder cancer may be at, you should schedule an appointment to see an oncologist specialising in bladder cancer as soon as possible. With the speed of developments in bladder cancer diagnosis and treatment, novel emerging treatment options could be explored by your medical oncologist.
Our cancer specialists at OncoCare specialise in treating late stage and advanced stages of bladder cancer, as well as earlier stages of the disease.
Senior Consultant, Medical Oncologist
MBBS (Delhi) – American Board Certified (Int Med) – American Board Certified (Hematology) – American Board Certified (Med Oncology)
Before joining OncoCare Cancer Centre at Mount Elizabeth Hospital, Singapore, Dr Akhil Chopra was a Senior Consultant in Medical Oncology at Johns Hopkins Singapore, Tan Tock Seng Hospital and Adjunct Associate Professor at Lee Kong Chian School of Medicine.
Dr Chopra has experience treating multiple cancer types including breast cancer, lung cancer, cancers of stomach, colon, rectum, liver, prostate, kidney, testicular and bladder, gynaecological cancers such as ovarian and uterine/cervical cancers; as well as Sarcomas and chronic leukaemia’s/multiple myeloma. Besides his clinical and research work, he has been involved in teaching medical students from the Lee Kong Chian School of Medicine as well as medical residents and students from Johns Hopkins University, Baltimore in USA.
Cancer Specialities: breast cancer, lung cancer, cancers of stomach, colon, rectum, liver, prostate, kidney, testicular and bladder, gynaecological cancers such as ovarian and uterine/cervical cancers
Senior Consultant, Medical Oncologist
MBBS (Singapore) – M.Med (Singapore) – MRCP (United Kingdom) – FAMS (Medical Oncology)
Dr Tay Miah Hiang, Senior Consultant Medical Oncologist at OncoCare Cancer Centre, was previously consultant at the National Cancer Centre Singapore’s Department of Medical Oncology, and Chairperson of Patient Education & Patient Survivorship programmes. Dr Tay also served on the board of Singapore Children’s Cancer Foundation from 2006 till 2015, and was Chairperson of this foundation from 2011 to 2013, and now serving as advisor. He is an elected member of Singapore Medical Council (SMC) since 2017 till date.
Dr Tay is passionate in contributing to Continuous Medical Education in the region, giving lectures in cancer management to cancer specialists, general practitioners, medical students and patients. He has won numerous awards for his service excellence and humanity contribution to disaster inflicted regions as such as post-Afghanistan war and Sri Lanka after Tsunami.
He has been actively involved in clinical and translational research for many years, in genitourinary (testicular, kidney, bladder, prostate), lung and other cancers. His research work is well published in hormone-refractory prostate cancer involved chemotherapy agents such as docetaxel and carboplatin. Acknowledged as a senior cancer specialist and an authority in prostate cancer in Singapore, he had also published on the use of ketoconazole and as part of a multi-centre clinical trial, the use of abiraterone acetate in metastatic castration-resistant prostate cancer progressing after chemotherapy.
As a pioneer in kidney cancer oncology, he had used sunitinib (Sutent), refametinib in kidney cancer patients when the drugs were coming into clinical practice in Singapore. Recognised as an authority in prostate cancer in Singapore, he had helped developed guidelines for the treatment of prostate cancer in Singapore in 2013 and the management of kidney cancer in Asia at the Asian Oncology Summit 2012.
His significant research work has been published in both local and international journals including Urology, Cancer, and Annals of Oncology. He also wrote chapters in several internationally recognised cancer specialty books such as Comprehensive Textbook of Genitourinary Oncology (3rd Edition), American Cancer Society’s Complete Guide to Prostate Cancer 2006, and Textbook on Urologic Oncology 2004.
Dr Tay is lauded for his experience in treating prostate, kidney, testicular and the bladder, gynaecological cancers such as ovarian cancer and uterine/cervical cancers, gastrointestinal & hepatobiliary cancers, lung cancer, brain tumour. He does not see patients with lymphoma, leukemia and breast cancer.
Bladder cancer is a type of cancer that begins in the cells of the bladder, which is a hollow organ in the lower abdomen that stores urine. The most common type of bladder cancer is urothelial carcinoma, also known as transitional cell carcinoma, which starts in the urothelial cells that line the inside of the bladder.
There are several types of bladder cancer, including:
Less common types of bladder cancer include small cell carcinoma, sarcoma, and lymphoma. These types are relatively rare and account for a small percentage of bladder cancer cases.
Bladder cancer is a significant global health concern. It ranks as the 10th most common cancer worldwide, accounting for around 3.2% of all new cancer cases. The disease primarily affects older individuals, with most cases occurring in people over the age of 55. The global mortality rate for bladder cancer is estimated to be approximately 2.8%.
In Singapore, bladder cancer is particularly prominent among males, ranking as the 5th most common cancer. However, it is less prevalent among females. In 2020, there were 1,004 new cases of bladder cancer reported in Singapore. The incidence rate stands at around 4.7 cases per 100,000 population, with a mortality rate of approximately 2.3 per 100,000 population.
These statistics provide a general overview of bladder cancer’s prevalence and impact both worldwide and in Singapore, emphasising the need for continued research, early detection, and effective treatment strategies to combat this disease.
Signs and symptoms of bladder cancer can vary, and some individuals may not experience any symptoms in the early stages.
It’s important to note that these symptoms can also be caused by other non-cancerous conditions, such as urinary tract infections or bladder stones. However, if any of these symptoms persist or cause concern, it is crucial to consult a healthcare professional for a proper evaluation and diagnosis.
Unlike some other cancers, there are no standard screening tests recommended for the general population to detect bladder cancer in its early stages. This is because there is currently insufficient evidence to support the effectiveness of routine screening for bladder cancer in individuals without any specific risk factors or symptoms.
However, in certain high-risk individuals, such as those with a history of bladder cancer or exposure to certain occupational hazards, regular screening or surveillance may be recommended. The specific screening or surveillance strategies may vary based on individual risk factors and medical history.
In general, if you have any symptoms suggestive of bladder cancer, such as blood in the urine (hematuria), frequent urination, or persistent urinary tract infections, it is important to consult a healthcare professional for a proper evaluation. They may perform tests such as urine analysis, imaging studies (like ultrasound or CT scan), or cystoscopy (a procedure to examine the bladder using a thin tube with a camera) to help diagnose or rule out bladder cancer.
Additionally, it’s worth noting that reducing exposure to known risk factors for bladder cancer, such as quitting smoking and minimising occupational exposure to certain chemicals, can help lower the risk of developing the disease.
Bladder cancer is typically diagnosed through a combination of medical history evaluation, physical examination, and diagnostic tests. The diagnostic process for bladder cancer may involve the following steps:
Once a diagnosis of bladder cancer is confirmed, further tests may be conducted to determine the stage of the cancer and whether it has spread to other parts of the body. This information is crucial for developing an appropriate treatment plan.
The exact causes of bladder cancer are not fully understood, but it is believed to develop due to a combination of genetic and environmental factors. Several risk factors have been identified that can increase the likelihood of developing bladder cancer.
These include:
Smoking: Smoking tobacco is the most significant risk factor for bladder cancer. Chemicals in tobacco smoke are absorbed into the bloodstream and excreted in the urine, directly exposing the bladder lining to carcinogens.
Occupational Exposure: Certain occupations involving exposure to chemicals such as aromatic amines, benzidine, and certain dyes, rubber, paint, and metalworking industries have been linked to an increased risk of bladder cancer.
Age and Gender: Bladder cancer occurs more frequently in older adults, with the risk increasing with age. Men are more likely to develop bladder cancer compared to women.
Previous Cancer Treatment: Individuals who have received certain cancer treatments, such as radiation therapy or certain chemotherapy drugs, particularly cyclophosphamide, have an increased risk of developing bladder cancer.
Chronic Bladder Inflammation: Chronic urinary tract infections, bladder stones, and long-term use of urinary catheters can cause chronic irritation and inflammation of the bladder, which may increase the risk of developing bladder cancer.
Family History: Bladder cancer has been observed to occur more frequently in some families, suggesting a genetic predisposition.
Diet and Lifestyle Factors: A diet low in fruits and vegetables and high in processed meats, as well as obesity, have been suggested as potential risk factors for bladder cancer.
It’s important to note that having one or more of these risk factors does not necessarily mean that an individual will develop bladder cancer. Conversely, some individuals with bladder cancer may not have any known risk factors. Understanding the risk factors can help individuals make informed lifestyle choices and undergo appropriate screening or preventive measures when necessary.
Bladder cancer can be classified into different types based on the specific cells that are affected. The main types of bladder cancer include:
Less common types of bladder cancer include small cell carcinoma, sarcoma, and lymphoma. These types account for a small percentage of bladder cancer cases.
The type of bladder cancer and its stage play a crucial role in determining the treatment approach and prognosis. A proper diagnosis is essential to guide appropriate treatment decisions, and healthcare professionals use various diagnostic tests, including biopsies and imaging, to determine the specific type and stage of bladder cancer in each individual case.
Bladder cancer staging refers to the process of determining the extent and spread of the cancer within the bladder and to nearby organs or lymph nodes. The stages of bladder cancer are typically classified using the TNM system, which stands for Tumour, Nodes, and Metastasis. The stages range from non-invasive (limited to the inner lining of the bladder) to invasive (spreading into deeper layers of the bladder or beyond). Here is a general overview of the stages of bladder cancer:
Staging plays a crucial role in determining the appropriate treatment options and predicting the prognosis for bladder cancer patients. Various diagnostic tests, such as imaging, biopsies, and sometimes surgical exploration, are done to accurately determine the stage of bladder cancer in each individual case.